S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 

Karuna Therapeutics (KRTX) Stock Forecast, Price & News

$227.62
-6.20 (-2.65%)
(As of 06/9/2023 ET)
Compare
Today's Range
$227.42
$234.52
50-Day Range
$176.32
$236.30
52-Week Range
$93.47
$278.25
Volume
284,836 shs
Average Volume
294,207 shs
Market Capitalization
$8.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$275.44

Karuna Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
21.0% Upside
$275.44 Price Target
Short Interest
Bearish
5.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of Karuna Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$12.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($11.46) to ($10.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

831st out of 987 stocks

Pharmaceutical Preparations Industry

408th out of 483 stocks


KRTX stock logo

About Karuna Therapeutics (NASDAQ:KRTX) Stock

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KRTX Stock News Headlines

Trade Smarter: Discover Hidden Opportunities w/ A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Citi Keeps Their Buy Rating on Karuna Therapeutics (KRTX)
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Karuna Therapeutics (NASDAQ:KRTX) Stock Price Down 5.6%
Berenberg Bank Remains a Buy on Karuna Therapeutics (KRTX)
See More Headlines

KRTX Price History

KRTX Company Calendar

Last Earnings
5/04/2023
Today
6/10/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRTX
Fax
N/A
Employees
118
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$275.44
High Stock Price Forecast
$330.00
Low Stock Price Forecast
$209.00
Forecasted Upside/Downside
+21.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-276,340,000.00
Net Margins
-2,795.96%
Pretax Margin
-2,783.40%

Debt

Sales & Book Value

Annual Sales
$11.29 million
Book Value
$32.78 per share

Miscellaneous

Free Float
31,378,000
Market Cap
$8.52 billion
Optionable
Not Optionable
Beta
1.15

Key Executives

  • William J. Meury
    President, Chief Executive Officer & Director
  • Andrew Miller
    Chief Operating Officer
  • Troy A. IgnelziTroy A. Ignelzi
    Chief Financial Officer
  • Stephen BrannanStephen Brannan
    Chief Medical Officer
  • Steven Marc PaulSteven Marc Paul
    Director, Chief Scientific Officer, President-R&D













KRTX Stock - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRTX shares.
View KRTX analyst ratings
or view top-rated stocks.

What is Karuna Therapeutics' stock price forecast for 2023?

15 brokerages have issued 12-month target prices for Karuna Therapeutics' shares. Their KRTX share price forecasts range from $209.00 to $330.00. On average, they predict the company's share price to reach $275.44 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price.
View analysts price targets for KRTX
or view top-rated stocks among Wall Street analysts.

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 at the beginning of 2023. Since then, KRTX shares have increased by 15.8% and is now trading at $227.62.
View the best growth stocks for 2023 here
.

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our KRTX earnings forecast
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($2.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.86) by $0.06. The company had revenue of $0.65 million for the quarter. Karuna Therapeutics had a negative trailing twelve-month return on equity of 30.04% and a negative net margin of 2,795.96%. During the same quarter in the previous year, the company earned ($1.95) EPS.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.97%), Price T Rowe Associates Inc. MD (6.63%), BlackRock Inc. (6.60%), Wellington Management Group LLP (4.29%), State Street Corp (2.66%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends
.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $227.62.

How much money does Karuna Therapeutics make?

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $8.52 billion and generates $11.29 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($9.57) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.

This page (NASDAQ:KRTX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -